Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib for Pediatric Acute Graft vs. Host Disease (REACH4)
NCT03491215Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Novartis. Primary endpoints: Area Under the Concentration-time Curve from Time Zero to the Last Measurable Concentration at Day 1, Maximum Serum Concentration at Day 1 and 2 more. Started Feb 2019; status: completed.
02
Drugs
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT03491215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03491215.